200 related articles for article (PubMed ID: 10777608)
21. On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II.
Lindsley JE; Wang JC
J Biol Chem; 1993 Apr; 268(11):8096-104. PubMed ID: 8385137
[TBL] [Abstract][Full Text] [Related]
22. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
23. ATPase domain of eukaryotic DNA topoisomerase II. Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization.
Hu T; Sage H; Hsieh TS
J Biol Chem; 2002 Feb; 277(8):5944-51. PubMed ID: 11850431
[TBL] [Abstract][Full Text] [Related]
24. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.
Dickey JS; Osheroff N
Biochemistry; 2005 Aug; 44(34):11546-54. PubMed ID: 16114891
[TBL] [Abstract][Full Text] [Related]
25. Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain.
McClendon AK; Gentry AC; Dickey JS; Brinch M; Bendsen S; Andersen AH; Osheroff N
Biochemistry; 2008 Dec; 47(50):13169-78. PubMed ID: 19053267
[TBL] [Abstract][Full Text] [Related]
26. The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.
Gilroy KL; Austin CA
PLoS One; 2011 Feb; 6(2):e14693. PubMed ID: 21358820
[TBL] [Abstract][Full Text] [Related]
27. Structure-function analysis of the ATPase domain of African swine fever virus topoisomerase.
Kuang W; Zhao Y; Li J; Deng Z
mBio; 2024 Apr; 15(4):e0308623. PubMed ID: 38411066
[TBL] [Abstract][Full Text] [Related]
28. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
29. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
30. Using a biochemical approach to identify the primary dimerization regions in human DNA topoisomerase IIalpha.
Bjergbaek L; Jensen S; Westergaard O; Andersen AH
J Biol Chem; 1999 Sep; 274(37):26529-36. PubMed ID: 10473615
[TBL] [Abstract][Full Text] [Related]
31. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity.
Schmidt BH; Osheroff N; Berger JM
Nat Struct Mol Biol; 2012 Nov; 19(11):1147-54. PubMed ID: 23022727
[TBL] [Abstract][Full Text] [Related]
32. Kinetic and thermodynamic analysis of mutant type II DNA topoisomerases that cannot covalently cleave DNA.
Morris SK; Harkins TT; Tennyson RB; Lindsley JE
J Biol Chem; 1999 Feb; 274(6):3446-52. PubMed ID: 9920889
[TBL] [Abstract][Full Text] [Related]
33. The ATP-operated clamp of human DNA topoisomerase IIalpha: hyperstimulation of ATPase by "piggy-back" binding.
Campbell S; Maxwell A
J Mol Biol; 2002 Jul; 320(2):171-88. PubMed ID: 12079377
[TBL] [Abstract][Full Text] [Related]
34. Yeast topoisomerase II is inhibited by etoposide after hydrolyzing the first ATP and before releasing the second ADP.
Morris SK; Lindsley JE
J Biol Chem; 1999 Oct; 274(43):30690-6. PubMed ID: 10521457
[TBL] [Abstract][Full Text] [Related]
35. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
37. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
38. Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.
Deweese JE; Guengerich FP; Burgin AB; Osheroff N
Biochemistry; 2009 Sep; 48(38):8940-7. PubMed ID: 19697956
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of Escherichia coli topoisomerase IV. II. ATPase negative mutants of parE induce hyper-DNA cleavage.
Nurse P; Bahng S; Mossessova E; Marians KJ
J Biol Chem; 2000 Feb; 275(6):4104-11. PubMed ID: 10660570
[TBL] [Abstract][Full Text] [Related]
40. Interaction of human DNA topoisomerase II alpha with DNA: quantification by surface plasmon resonance.
Renodon-Cornière A; Jensen LH; Nitiss JL; Jensen PB; Sehested M
Biochemistry; 2002 Nov; 41(45):13395-402. PubMed ID: 12416984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
